114.23

1.61% 1.81

Abbott Laboratories (ABT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$112.42

Aprire:

$112.64

Volume 24 ore:

9.92M

Relative Volume:

2.11

Capitalizzazione di mercato:

$198.13B

Reddito:

$41.22B

Utile/perdita netta:

$5.77B

Rapporto P/E:

38.85

EPS:

2.94

Flusso di cassa netto:

$6.49B

1 W Prestazione:

+0.75%

1M Prestazione:

-1.47%

6M Prestazione:

+7.19%

1 anno Prestazione:

+6.36%

Intervallo 1D:

$112.52

$115.11

Intervallo di 1 settimana:

$111.28

$115.11

Portata 52W:

$99.71

$121.64

Abbott Laboratories Stock (ABT) Company Profile

Nome

Abbott Laboratories

Settore

Healthcare (1176)

Industria

Medical Devices (148)

Telefono

(224) 667-6100

Indirizzo

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Dipendente

114,000

Cinguettio

@AbbottNews

Prossima data di guadagno

2024-10-16

Ultimi documenti SEC

ABT's Discussions on Twitter

Confronta ABT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ABT Abbott Laboratories	114.23	198.13B	41.22B	5.77B	6.49B	3.29
SYK Stryker Corp	364.60	138.99B	21.97B	3.59B	3.21B	9.33
BSX Boston Scientific Corp	88.95	131.10B	15.91B	1.79B	1.89B	1.21
MDT Medtronic Plc	81.03	103.90B	33.00B	4.29B	5.50B	3.27
EW Edwards Lifesciences Corp	74.81	44.12B	6.60B	4.16B	490.10M	6.93

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-08	Iniziato	Oppenheimer	Outperform
2024-09-19	Iniziato	Piper Sandler	Overweight
2024-07-30	Downgrade	Edward Jones	Buy → Hold
2024-05-30	Iniziato	Goldman	Buy
2023-07-21	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2023-05-30	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2023-04-20	Reiterato	Barclays	Overweight
2023-04-20	Reiterato	Bernstein	Outperform
2023-04-20	Reiterato	JP Morgan	Overweight
2023-04-20	Reiterato	Raymond James	Outperform
2023-04-20	Reiterato	UBS	Buy
2023-04-20	Reiterato	Wolfe Research	Underperform
2023-03-29	Iniziato	UBS	Buy
2022-10-26	Iniziato	Mizuho	Neutral
2022-10-18	Iniziato	Barclays	Overweight
2022-10-12	Iniziato	Jefferies	Hold
2022-07-06	Iniziato	Wolfe Research	Underperform
2022-03-02	Ripresa	BofA Securities	Buy
2022-01-27	Reiterato	Credit Suisse	Outperform
2022-01-27	Reiterato	Morgan Stanley	Overweight
2022-01-27	Reiterato	Raymond James	Outperform
2022-01-27	Reiterato	UBS	Buy
2021-12-10	Iniziato	RBC Capital Mkts	Outperform
2021-10-27	Aggiornamento	Atlantic Equities	Neutral → Overweight
2021-10-14	Iniziato	Redburn	Neutral
2021-05-25	Iniziato	Barclays	Overweight
2021-04-15	Iniziato	Atlantic Equities	Neutral
2021-01-28	Aggiornamento	BTIG Research	Neutral → Buy
2020-09-11	Iniziato	Wolfe Research	Outperform
2020-06-01	Downgrade	Goldman	Neutral → Sell
2020-03-05	Iniziato	Citigroup	Buy
2020-02-13	Iniziato	Goldman	Neutral
2020-02-06	Ripresa	BTIG Research	Neutral
2020-01-02	Downgrade	Guggenheim	Buy → Neutral
2019-06-13	Reiterato	BofA/Merrill	Buy
2019-02-07	Reiterato	BofA/Merrill	Buy
2019-01-02	Downgrade	Citigroup	Neutral → Sell
2018-11-30	Aggiornamento	Goldman	Neutral → Buy
2018-10-16	Iniziato	Barclays	Overweight
2018-06-27	Iniziato	Bernstein	Outperform
2018-01-30	Reiterato	Citigroup	Neutral
2018-01-25	Reiterato	Stifel	Buy
2018-01-25	Aggiornamento	William Blair	Mkt Perform → Outperform
2018-01-03	Iniziato	Evercore ISI	Outperform
2018-01-02	Aggiornamento	JP Morgan	Neutral → Overweight
2018-01-02	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2017-10-19	Reiterato	RBC Capital Mkts	Outperform
2017-10-19	Reiterato	Stifel	Buy

Mostra tutto

Abbott Laboratories Borsa (ABT) Ultime notizie

04:31 AM

M&T Bank Corp Has $110.42 Million Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat

04:31 AM

04:27 AM

Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline - Seeking Alpha

04:27 AM

Dec 20, 2024

Abbott Whistleblower's False Claims Suit is Revived, Narrowed - Bloomberg Law

Dec 20, 2024

Abbott Labs stock target increased, buy rating on strong product lineup - Investing.com

Dec 20, 2024

The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories - Yahoo Finance

Dec 20, 2024

XTX Topco Ltd Sells 31,480 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat

Dec 20, 2024

Abbott Laboratories (NYSE:ABT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Dec 20, 2024

Dec 19, 2024

Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch

Dec 19, 2024

Abbott announces “first-in-world” leadless pacing procedures in left bundle branch area of heart - Cardiac Rhythm News

Dec 19, 2024

Implantable Loop Recorder Market Top Companies StudyAbbott - openPR

Dec 19, 2024

Dec 18, 2024

Syntax Research Inc. Makes New $2.28 Million Investment in Abbott Laboratories (NYSE:ABT) - MarketBeat

Dec 18, 2024

The Smartest Dividend Stocks to Buy With $500 Right Now - The Motley Fool

Dec 18, 2024

Biochips Market Huge Growth in Future Scope 2024-2031 | Abbott - openPR

Dec 18, 2024

Dec 17, 2024

Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Dec 17, 2024

Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Dec 17, 2024

Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker - Cardiovascular Business

Dec 17, 2024

Abbott completes first-in-human leadless left bundle branch area pacing procedures - Mass Device

Dec 17, 2024

Cardiac Biomarkers Market CAGR of 13.3% Size, Current Trends, Future Prospects By 2024-2031 | Abbott - EIN News

Dec 17, 2024

Are Abbott Laboratories' (NYSE:ABT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? - Yahoo Finance

Dec 17, 2024

Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart - The Eastern Progress Online

Dec 17, 2024

Dec 16, 2024